187 research outputs found

    Payment Rules through Discriminant-Based Classifiers

    Get PDF
    pdf: publications/dfjo_svmmd.pdf ps: publications/dfjo_svmmd.ps.gz tr: http://arxiv.org/abs/1208.1184 slides: publications/slides_svmmd.pdf http: http://dx.doi.org/10.1145/2559049 keywords: web,journal,selected,recent webnote: Earlier version appeared in the proc13thecold sort: 1401a cvnote: \contrib16%\selectedpdf: publications/dfjo_svmmd.pdf ps: publications/dfjo_svmmd.ps.gz tr: http://arxiv.org/abs/1208.1184 slides: publications/slides_svmmd.pdf http: http://dx.doi.org/10.1145/2559049 keywords: web,journal,selected,recent webnote: Earlier version appeared in the proc13thecold sort: 1401a cvnote: \contrib16%\selecte

    Payment Rules through Discriminant-Based Classifiers

    Get PDF
    In mechanism design it is typical to impose incentive compatibility and then derive an optimal mechanism subject to this constraint. By replacing the incentive compatibility requirement with the goal of minimizing expected ex post regret, we are able to adapt statistical machine learning techniques to the design of payment rules. This computational approach to mechanism design is applicable to domains with multi-dimensional types and situations where computational efficiency is a concern. Specifically, given an outcome rule and access to a type distribution, we train a support vector machine with a special discriminant function structure such that it implicitly establishes a payment rule with desirable incentive properties. We discuss applications to a multi-minded combinatorial auction with a greedy winner-determination algorithm and to an assignment problem with egalitarian outcome rule. Experimental results demonstrate both that the construction produces payment rules with low ex post regret, and that penalizing classification errors is effective in preventing failures of ex post individual rationality

    Effect of Probiotic Lactobacillus (Lacidofil® Cap) for the Prevention of Antibiotic-associated Diarrhea: A Prospective, Randomized, Double-blind, Multicenter Study

    Get PDF
    Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. There is growing interest in probiotics for the treatment of AAD and Clostridium difficile infection because of the wide availability of probiotics. The aim of this multicenter, randomized, placebo-controlled, double-blind trial was to assess the efficacy of probiotic Lactobacillus (Lacidofil® cap) for the prevention of AAD in adults. From September 2008 to November 2009, a total of 214 patients with respiratory tract infection who had begun receiving antibiotics were randomized to receive Lactobacillus (Lacidofil® cap) or placebo for 14 days. Patients recorded bowel frequency and stool consistency daily for 14 days. The primary outcome was the proportion of patients who developed AAD within 14 days of enrollment. AAD developed in 4 (3.9%) of 103 patients in the Lactobacillus group and in 8 (7.2%) of 111 patients in the placebo group (P=0.44). However, the Lactobacillus group showed lower change in bowel frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) (P=0.01). Although the Lacidofil® cap does not reduce the rate of occurrence of AAD in adult patients with respiratory tract infection who have taken antibiotics, the Lactobacillus group maintains their bowel habits to a greater extent than the placebo group

    Dissecting the physiology and pathophysiology of glucagon-like peptide-1

    Get PDF
    Copyright © 2018 Paternoster and Falasca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. An aging world population exposed to a sedentary life style is currently plagued by chronic metabolic diseases, such as type-2 diabetes, that are spreading worldwide at an unprecedented rate. One of the most promising pharmacological approaches for the management of type 2 diabetes takes advantage of the peptide hormone glucagon-like peptide-1 (GLP-1) under the form of protease resistant mimetics, and DPP-IV inhibitors. Despite the improved quality of life, long-term treatments with these new classes of drugs are riddled with serious and life-threatening side-effects, with no overall cure of the disease. New evidence is shedding more light over the complex physiology of GLP-1 in health and metabolic diseases. Herein, we discuss the most recent advancements in the biology of gut receptors known to induce the secretion of GLP-1, to bridge the multiple gaps into our understanding of its physiology and pathology

    The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality

    Get PDF
    Background Most diarrhoeal deaths can be prevented through the prevention and treatment of dehydration. Oral rehydration solution (ORS) and recommended home fluids (RHFs) have been recommended since 1970s and 1980s to prevent and treat diarrhoeal dehydration. We sought to estimate the effects of these interventions on diarrhoea mortality in children aged <5 years

    Reply

    No full text

    Getting Started in Global Health: A Practical Guide for Gastroenterology Fellows

    No full text
    corecore